Compare Amgen, Inc. (AMGN) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Enphase Energy Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Enphase Energy Inc trades at $40.75 (market cap $5.59B). The key difference: Amgen, Inc. is far larger — about 40.1× Enphase Energy Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| AMGN | ENPH | |
|---|---|---|
Market Cap | $224.14B | $5.59B |
Sector | Health | Technology |
52-Week High | $417.20 | $72.33 |
52-Week Low | $271.18 | $26.12 |
Enterprise Value | $267.45B | $5.23B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Enphase Energy (ENPH) trades at $40.86, down 0.15% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings that matched estimates but missed revenue expectations, with revenue declining 19.6% year-over-year. Recent news highlights product expansion including IQ Battery 10C support for third-party systems and reinforced U.S. manufacturing commitments across residential, commercial and AI infrastructure segments.
While analyst consensus remains cautiously optimistic with a $45.37 price target, ENPH faces headwinds from cyclical residential solar demand and competitive pressures. The stock offers potential upside if the company can execute on its storage-led recovery strategy and capitalize on AI data center opportunities, though investors should monitor execution risks and market volatility in the solar sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
